Biblio

Author Title [ Type

] Year

Filters: Author is Botta, Cirino [Clear All Filters]

Journal Article

Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, et al. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. Eur J Haematol. 2021.

Morabito F, Tripepi G, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, et al. Assessment of the 4-factor score: retrospective analysis of 586 cll patients receiving ibrutinib. A campus cll study. Am J Hematol. 2021.

Botta C, Maia CDa Silva, Garcés J-J, Termini R, Perez C, Manrique I, Burgos L, Zabaleta A, Alignani D, Sarvide S, et al. FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology. Blood Adv. 2021.

Morabito F, Recchia AGrazia, Vigna E, Botta C, Skafi M, Abu-Rayyan M, Atrash M, Galimberti S, Morabito L, Al-Janazreh H, et al. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opin Pharmacother. 2019:1-10.

Fazio M, Del Fabro V, Parrinello NLaura, Allegra A, Markovic U, Botta C, Accardi F, Vincelli IDonatella, Leotta S, Elia F, et al. Multiple Myeloma in 2023 Ways: From Trials to Real Life. Curr Oncol. 2023;30(11):9710-9733.

Rodríguez S, Celay J, Goicoechea I, Jimenez C, Botta C, Garcia-Barchino M-J, Garcés J-J, Larrayoz M, Santos S, Alignani D, et al. Preneoplastic somatic mutations including in lymphoplasmacytic lymphoma. Sci Adv. 2022;8(3):eabl4644.